Hyman, David M <br/><br/>
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.  [electronic resource] 

 -  Gynecologic oncology  Nov 2011 
 - 196-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1095-6859 
<br/><br/><label>Standard No.: </label>10.1016/j.ygyno.2011.07.019  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Disease-Free Survival<br/>Drug Resistance, Neoplasm<br/>Fallopian Tube Neoplasms--drug therapy<br/>Female<br/>Genes, BRCA1<br/>Genes, BRCA2<br/>Humans<br/>Middle Aged<br/>Mutation<br/>Ovarian Neoplasms--drug therapy<br/>Peritoneal Neoplasms--drug therapy<br/>Platinum--therapeutic use<br/>Retrospective Studies<br/>Topoisomerase I Inhibitors--therapeutic use<br/>Topotecan--therapeutic use